Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 276-541-3 | CAS number: 72252-61-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on animal welfare considerations a combination of non-animal methods in form of an adverse outcome pathway was performed to assess skin sensitisation potential of the test item. These non-animal approaches contain the molecular initiating event of skin sensitisation (in-chemicoprotein reactivity-OECD TG 442c) and the intermediate events (in-vitroARE-Nrf2 Luciferase Test Method OECD TG 442d and dendritic cell activation OECD 442e).
Due to the equivocal results of these test methods and the limited applicability especially for the tested metallic compounds further in-vivo testing (LLNA-OECD TG 429) for assessing skin sensitisation potential of the test item was performed. Based on the LLNA the test item can be considered as a moderate skin sensitiser.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2018-01-03 to 2018-04-30
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- according to OECD and GLP guidelines
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- July 2010
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- May 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2600 (Skin Sensitisation)
- Version / remarks:
- March 2003
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany)
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- Species/strain: healthy CBA/CaOlaHsd mice
Source: Envigo (formed partially from Harlan in September 2015), 5800 AN Venray, The Netherlands
Sex: female (nulliparous and non-pregnant)
Age at the beginning of the study: 8-9 weeks
Number of animals: 5 mice / group; 5 mice / prescreen test
The animals were derived from a controlled full-barrier maintained breeding system (SPF). According to the German Act on Animal Welfare the animals were bred for experimental purposes.
This study was performed in an AAALAC-accredited laboratory. According to German animal protection law, the study type has been reviewed and accepted by local authorities. Furthermore, the study has been subjected to Ethical Review Process and was authorised by the Bavarian animal welfare administration.
- Full barrier in an air-conditioned room
- Temperature: 22 ± 3 °C
- Relative humidity: 55 ± 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: at least 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice
- Free access to tap water, sulphur acidified to a pH value of approx. 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept in groups of 5 animals in IVC cages, type II L, polysulphone cages on Altromin saw fibre bedding
- Certificates of food, water and bedding are filed for two years at BSL Munich and afterwards archived at Eurofins Munich
- Adequate acclimatisation period (at least five days) under laboratory conditions - Vehicle:
- dimethyl sulphoxide
- Remarks:
- Sigma-Aldrich, lot no. SHBG5154V, expiry date: 03/2019
- Concentration:
- Based on the results observed in the prescreen test the following test item concentrations were selected for the main study:
6.25%, 12.5% and 25% (w/v)
The preparations were made immediately prior to each dosing. - No. of animals per dose:
- 5 animals/dose group, 5 animals/control group
5 mice / prescreen test - Details on study design:
- Prescreen Test
Before the initiation of the prescreen test, a solubility test was performed to define the vehicle and the maximum concentration which is technically applicable to the animals.
The maximum technically applicable concentration of the test item in the vehicle was found to be 25% in DMSO (Sigma-Aldrich, lot no. SHBF2742V, expiry date: 17/03/2019).
In order to determine the highest tolerated and not excessively irritant test concentration a prescreen test was performed which was conducted under the same conditions as the main study, except there was no assessment of lymph node proliferation. The mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Body weights were recorded pre-test and prior to termination. Both ears were observed for erythema and scored. Ear thickness measurements were performed on day 1 (pre-dose), day 3 (approximately 48 hours after the first dose) and day 6. Excessive local irritation was indicated by an erythema score ≥ 3 and/or ear swelling of ≥ 25%.
Four animals were treated by topical application with the test item on three consecutive days at the following concentrations to the entire dorsal surface of each ear:
Animals no. 51 and no. 52 were treated with a test item concentration of 25% (suspended in DMSO)
Animals no. 53 and no. 54 were treated with a test item concentration of 12.5% (suspended with DMSO)
One further animal was treated with 100% DMSO and served as negative control (animal no. 55).
Immediately before the first application, approximately 48 hours after the first application and shortly before sacrificing the thickness of both ears of all animals was measured.
During this period also all clinical signs were recorded.
Cageside observations included spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in the skin and fur, eyes and mucous membranes (salivation, discharge).
Neither signs of systemic toxicity nor signs of excessive irritation at any application site could be detected in any animal.
All animals showed the expected weight development, which includes a weight loss of up to 2 g throughout the duration of the prescreen test.
Based on the results observed in the prescreen test the following test item concentrations were selected for the main study:
6.25%, 12.5% and 25% (w/v)
The preparations were made immediately prior to each dosing.
Based on the results observed in the prescreen test the following test item concentrations were selected for the main study:
6.25%, 12.5% and 25% (w/v)
The preparations were made immediately prior to each dosing.
Controls
DMSO was used as vehicle and served as negative control.
For animal welfare reasons the negative control was shared.
Positive controls are performed periodically. The recent results are included in the report.
Preparation of the Animals
The animals were randomly selected using the validated departmental computerised system E WorkBook (latest version, ID Business Solutions Ltd.).
Identification was ensured by cage number and individual marking (tail).
Clinical Observation
Prior to the application and once a day thereafter all animals were observed in order to detect signs of toxicity, including dermal irritation at site of application.
Weight Assessment
The animals were weighed prior to the application and at the end of the test period (prior to the treatment with 3HTdR).
Dose Groups
3 test groups (3 different concentrations) and 1 negative control group (vehicle) were tested.
Test Regime
Topical Application
Immediately before the first application the thickness of both ears of all animals was measured. Each mouse was treated by topical application of
25 µL of the selected solution to the entire dorsal surface of each ear. A second measurement of the ear thickness of all animals was carried out
approximately 48 hours after the first application.
Topical applications were performed once daily over three consecutive days. The first treatment day is defined as study day 1.
Administration of 3H-Methyl Thymidine
Five days after the first topical application all mice were dosed with 20 µCi 3H-methyl thymidine by intravenous injection (tail vein) of 250 µL of
3H-methyl thymidine, diluted with PBS to a working concentration of 80 µCi/mL.
Preparation of Cell Suspension
Approximately 5 hours after the injection of 3H-methyl thymidine all mice were sacrificed by cervical dislocation. Shortly before sacrificing the
thickness of the ears of all animals was measured for a third time. The draining auricular lymph nodes were excised, individually pooled for each
animal (2 lymph nodes per animal) and collected in phosphate buffered saline (PBS). A single cell suspension of pooled lymph node cells was
prepared by gentle mechanical disaggregation through polyamide gauze (200 mesh size). After washing the gauze with PBS the cell suspension
was pelleted in a centrifuge. The supernatant was discarded and the pellets were resuspended with PBS. This washing procedure was repeated.
After the final wash each pellet was resuspended in approx. 1 mL 5% TCA at approx. 4 °C for approximately 18 hours for precipitation of
macromolecules. Each precipitate was once washed again, resuspended in 1 mL 5% TCA and 7 mL scintillation fluid was added. Then this solution
was transferred into scintillation vials and stored at room temperature overnight.
Determination of Incorporated 3H-Methyl Thymidine
The 3H-methyl thymidine – incorporation was measured in a ß-counter and expressed as the number of disintegrations per minute (DPM).
Similarly, background 3H-methyl thymidine levels were also measured (5% TCA). Determination of radioactivity was performed individually for
each animal.
This measurement was performed twice. The initial measurement is considered invalid due to technical reasons. The second measurement was
performed approximately one month after first measurement. As the 3-H half-life time is 12.32 years an influence on the measured activity is
excluded. - Positive control substance(s):
- other: Phenylenediamine
- Statistics:
- Outlier tests according to Dixon, Grubbs and Nalimov were performed for the values measured for the number of disintegrations per minute (DPM).
If outliers were identified, these values were not included in the calculation of the stimulation indices. As at least four values per group are required
for the evaluation of the results, the outlier test was not repeated to detect further outliers. - Positive control results:
- A shared positive control was performed concomitantly, using 5 animals.
1% phenylenediamine (Sigma-Aldrich, lot no.: WXBC3008V, expiry date 01/03/2019) in DMSO was used as positive-control substance. The Stimulation Index was 8.4. - Key result
- Parameter:
- SI
- Remarks on result:
- other: see Remark
- Remarks:
- One of the three tested concentrations exceeded the stimulation index of 3. The stimulation index at a concentration of 6.25% was 0.5 The stimulation index at a concentration of 12.5% was 1.3 The stimulation index at a concentration of 25% was 3.2
- Key result
- Parameter:
- SI
- Value:
- 0.5
- Test group / Remarks:
- Stimulation with a concentration of 6.25%
- Key result
- Parameter:
- SI
- Value:
- 1.3
- Test group / Remarks:
- Stimulation with a concentration of 12.5%
- Key result
- Parameter:
- SI
- Value:
- 3.2
- Test group / Remarks:
- Stimulation with a concentration of 25%
- Key result
- Parameter:
- EC3
- Value:
- 23.64
- Remarks on result:
- other:
- Remarks:
- calculated EC3 = 23.64%
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Conclusions:
- The test item was tested in dose groups of 6.25%, 12.5% and 25%. The test item showed a stimulation index of >3 at a concentration of 25%. The EC3 value (derived by linear interpolation) was calculated to be at a test item concentration of 23.64%, which provides an estimation of sensitisation potency.
The results of the radioactivity determination are supported by the second endpoint, the means of the lymph node weights per group, which showed increased values for the 25% test group compared to the negative control values.
According to Commission Regulation (EU) No 286/2011 (CLP) as well as GHS (Globally Harmonized Classification System) the test item Sanodure Fast Gold L dried has obligatory labelling requirement for skin sensitisation and is classified into Category 1B. - Executive summary:
On the basis of the test results given below and in conformity with the criteria given in Commission Regulation (EU) No 286/2011 the substance should be:
classified into sub-category 1A
classified into sub-category 1B
X
unclassified
On the basis of the test results given below and in conformity with the criteria given in GHS (Globally Harmonized Classification System) the substance should be:
classified into sub-category 1A
classified into sub-category 1B
X
unclassified
Based on the results of the prescreen test the test item was assessed for sensitising properties at concentrations of 6.25%, 12.5% and 25% (w/v), each suspended in dimethyl sulphoxide (DMSO).
Species/strain: mice, CBA/CaOlaHsd
Number of animals: 20 / main test
Vehicle: DMSO
Summary Results
There was no mortality and there were no significant clinical observations or effects on body weights.
One of the three tested concentrations exceeded the stimulation index of 3.
The stimulation index at a concentration of 6.25% was 0.5
The stimulation index at a concentration of 12.5% was 1.3
The stimulation index at a concentration of 25% was 3.2
There was a relevant increase in lymph node weight in the 25% test group compared to the negative control group.
The mean weight of the lymph node
for the 6.25% test group was 1.9 mg
for the 12.5% test group was 2.5 mg
for the 25% test group was 3.2 mg
for the negative-control group was 2.5 mg
Conclusion
The test item Sanodure Fast Gold L was tested in dose groups of 6.25%, 12.5% and 25%. The test item showed a stimulation index of >3 at a concentration of 25%. The EC3 value (derived by linear interpolation) was calculated to be at a test item concentration of 23.64%, which provides an estimation of sensitisation potency. Based on this value the test item can be considered as a moderate sensitiser.
The results of the radioactivity determination are supported by the second endpoint, the means of the lymph node weights per group, which showed increased values for the 25% test group compared to the negative control values.
According to Commission Regulation (EU) No 286/2011 (CLP) as well as GHS (Globally Harmonized Classification System) the test item Sanodure Fast Gold L dried has obligatory labelling requirement for skin sensitisation and is classified into Category 1B.
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-07-04 to 2017-09-09
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- according to OECD and GLP guidelines
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Version / remarks:
- February 2015
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Direct Peptide Reactivity Assay (DPRA) for Skin Sensitization Testing, DB-ALM Protocol n°154, January 12, 2013
- Version / remarks:
- January 2013
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- other: (in chemico) reactivity against synthetic peptides with a thiol or amino group
- Details on the study design:
- The in chemico direct peptide reactivity assay (DPRA) enables detection of the sensitising potential of a test item by quantifying the reactivity of test chemicals towards synthetic peptides containing either lysine or cysteine.
- Positive control results:
- The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 66.77%.
- Key result
- Run / experiment:
- other: cysteine run
- Parameter:
- other: mean peptide depletion [%]
- Value:
- 100
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: lysine run
- Parameter:
- other: mean peptide depletion [%]
- Value:
- 3.76
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Other effects / acceptance of results:
- Acceptance Criteria
The run meets the acceptance criteria if:
- the standard calibration curve has a r² > 0.99,
- the mean percent peptide depletion (PPD) value of the three replicates for the positive control is
between 60.8% and 100% for the cysteine peptide and the maximum standard deviation (SD) for the
positive control replicates is < 14.9%,
- the mean percent peptide depletion (PPD) value of the three replicates for the positive control is
between 40.2% and 69.0% for the lysine peptide and the maximum SD for the positive control
replicates is < 11.6%,
- the mean peptide concentration of the three reference controls A replicates is 0.50 ± 0.05 mM,
- the coefficient of variation (CV) of peptide peak areas for the six reference control B replicates and three reference control C replicates in acetonitrile is < 15.0%.
The results of the test item meet the acceptance criteria if:
- the maximum standard deviation (SD) for the test chemical replicates is < 14.9% for the cysteine
percent depletion (PPD),
- the maximum standard deviation (SD) for the test chemical replicates is < 11.6% for the lysine
percent depletion (PPD),
- the mean peptide concentration of the three reference controls C replicates in the appropriate solvent is 0.50 ± 0.05 mM.
Both peptide runs and the test item results met the acceptance criteria of the test. - Conclusions:
- In this study under the given conditions the test item showed high reactivity towards the cysteine peptide and might be considered as sensitiser. It should be noted that according to the guideline 442C metal compounds might not fall within the applicability domain of the DPRA. However, the data generated with this test should be considered in the context of integrated approached such as IATA, combining the result with other complementary information, e.g. derived from in vitro assays addressing other key events of the skin sensitisation AOP.
- Executive summary:
In the present study the test item was dissolved in dist. water based on the results of the pre-experiments and a 100 mM stock solution was prepared. The test item solutions were tested by incubating the samples with the peptides containing either cysteine or lysine for 24 ± 2 h at 25 ± 2.5 °C. Subsequently samples were analysed by HPLC.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the cysteine peptide solution. After the 24 h±2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. A slight precipitate was observed for the samples of the test item .Samples were not centrifuged prior to the HPLC analysis.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the lysine peptide solution. After the 24 h±2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. Phase separation was observed for the samples of the positive control including the co-elution control of the positive control. Samples were not centrifuged prior to the HPLC analysis.
No co-elution of test item with the peptide peaks was observed, however, a slight precipitation was observed in the cysteine peptide experiment. Whereas negative results in combination with a precipitation cannot be evaluated as absence of sensitising potential, positive results can still be used. Sensitising potential of the test item was predicted from the mean peptide depletion of both analysed peptides (cysteine and lysine) by comparing the peptide concentration of the test item treated samples to the corresponding reference control C (RC C).
The 100 mM stock solution of the test item showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was > 6.38% (51.88%). Based on prediction model 1 the test item might be considered as sensitiser.
The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 66.77%.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-07-04 to 2017-10-15
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- according to OECD and GLP guidelines
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
- Version / remarks:
- February 2015
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: KeratinoSens™, EURL ECVAM DB-ALM Protocol No. 155, July 1st, 2015
- Version / remarks:
- July 2015
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- activation of keratinocytes
- Details on the study design:
- The in vitro KeratinoSens™ assay enables detection of the sensitising potential of a test item by addressing the second molecular key event of the adverse outcome pathway (AOP), namely activation of keratinocytes, by quantifying the luciferase activity in the transgenic cell line KeratinoSens™. The luciferase activity, assessed by luminescence measurement, compared to the respective solvent controls is used to support discrimination between skin sensitisers and non-sensitisers.
- Positive control results:
- The luciferase activity induced by the positive control at a concentration of 64 µM was between 2 and 8 (2.55 in experiment 1; 3.62 in experiment 2).
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: luciferase activity
- Remarks:
- I max
- Value:
- 44.12
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration
- Remarks:
- 250 µM
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: cell viability [%]
- Value:
- 115.5
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other:
- Remarks:
- Concentration 250 µM
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: EC1.5 [µM]
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not determinable
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: luciferase activity
- Value:
- 37.78
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration
- Remarks:
- 250 µM
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: cell viability [%]
- Value:
- 78.4
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other:
- Remarks:
- Concentration 250 µM
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: EC1.5 [µM]
- Value:
- 1.78
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not determinable
- Other effects / acceptance of results:
- Acceptance Criteria
The test meets acceptance criteria if:
- the luciferase activity induction of the positive control is statistically significant above the threshold of 1.5 (using a t-test) in at least one of the tested concentrations
- the average induction in the three technical replicates for the positive control at a concentration of
64 µM is between 2 and 8
- the EC1.5 value of the positive control is within two standard deviations of the historical mean
- the average coefficient of variation (CV; consisting of 6 wells) of the luminescence reading for the
negative (solvent) control DMSO is <20% in each repetition.
The controls fullfilled the validity criteria of the test. - Conclusions:
- In this study under the given conditions the test item did induce the luciferase activity in the transgenic KeratinoSens™ cell line in at least two independent experiment runs. Therefore, the test item might be considered as sensitiser. The data generated with this test should be considered in the context of integrated approached such as IATA, combining the result with other complementary information, e.g. derived from in vitro assays addressing other key events of the skin sensitisation AOP.
- Executive summary:
In the present study Aluminium Fast Gold L dried was dissolved in dist. water and aBased on a molecular weight of 559.93 g/mol a stock solution of 200 mM was prepared. A factor of 1.24 was used to correct for the purity of the test item.
Based on the stock solution a set of twelve master solutions in 100% solvent was prepared by serial dilution using a constant dilution factor of 1:2. These master solutions were diluted 1:100 in cell culture medium. The following concentration range was tested in the assay:
2000, 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98 µM
Cells were incubated with the test item for 48 h at 37°C. After exposurecells were lysed and luciferase activity was assessed by luminescence measurement.
In the first experiment, a max luciferase activity (Imax) induction of 44.12 was determined at a test item concentration of 250 µM. The corresponding cell viability was 115.5%. Since no luciferase induction < 1.5 with a viability > 70% was found, no EC1.5value could be calculated. Cytotoxicity was observed in the concentration range 500 µM – 2000 µM. A medium precipitation was observed in the concentration 500 µM, strong precipitation was observed in the concentrations 1000 µM – 2000 µM.
In the second experiment, a max luciferase activity (Imax) induction of 37.78 was determined at a test item concentration of 250 µM. The corresponding cell viability was 78.4%. The lowest tested concentration with a significant luciferase induction > 1.5 (1.54) was found to be 1.95 µM. The corresponding cell viability was > 70% (108.1%). The calculated EC1.5 was< 1000 µM (1.78 µM). Cytotoxicity was observed in the concentration range 500 µM – 2000 µM. A slight precipitation was observed in the concentration 250 µM, medium precipitation was observed in the concentrations 500 µM – 2000 µM.
The substance showed a tendency to reduce MTT, therefore, the cells were washed thoroughly. However, test item residues with potential to reduce MTT cannot be excluded. The high values of cell viability might be explained by this phenomenon. Furthermore, the high luciferase induction values in the higher test item concentrations could be indicating cell stress.
Although no EC1.5 could be calculated in the first experiment because the lowest concentration already showed an induction > 1.5, the EC1.5 must be < 1000 µM. All (other) criteria for sensitising potential are fulfilled. Furthermore, a dose response for luciferase activity induction was observed in the non-cytotoxic concentrations for each individual run as well as for an overall luciferase activity induction. Therefore, under the conditions of this study the test item might be considered as sensitiser.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-07-04 to 2017-09-15
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- according to OECD and GLP guidelines
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guidelines for Testing of Chemicals, No. 442E: “In vitro Skin Sensitisation: human Cell Line Activation Test (h-CLAT)” adopted 29 July 2016
- Version / remarks:
- July 2016
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Human Cell Line Activation Test (h-CLAT) for Skin Sensitisation, DB-ALM Protocol n°158, July 1st, 2015
- Version / remarks:
- July 2015
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- activation of dendritic cells
- Details on the study design:
- The in vitro human cell line activation test (h-CLAT) enables detection of the sensitising potential of a test
item by addressing the third molecular key event of the adverse outcome pathway (AOP), namely
dendritic cell activation, by quantifying the expression of the cell surface markers CD54 and CD86 in
the human monocytic cell line THP-1. The expression of the cell surface markers compared to the
respective solvent controls is used to support discrimination between skin sensitisers and
non-sensitisers. - Key result
- Run / experiment:
- other: 1
- Parameter:
- other: relative fluorescence intensity CD86 [%]
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not measured/tested
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: relative fluorescence intensity CD54 [%]
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not measured/tested
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: relative fluorescence intensity CD86 [%]
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not measured/tested
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: relative fluorescence intensity CD54 [%]
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not measured/tested
- Other effects / acceptance of results:
- Acceptance criteria:
The test meets acceptance criteria if:
• the cell viability of the solvent controls is >90%,
• the cell viability of at least four tested doses of the test item in each run is >50%,
• the RFI values of the positive control (DNCB) is ≥150% for CD86 and ≥200% for CD54 at a cell viability of >50%,
• the RFI values of the solvent control is not ≥150% for CD86 and not ≥200% for CD54,
• the MFI ratio of CD86 and CD54 to isotype IgG1 control for the medium and DMSO control, is >105%.
The test mets the acceptance criteria. - Conclusions:
- In the present study the test item was dissolved in 0.9% NaCl. For the dose finding assay stock solutions with concentrations ranging from 100.0 mg/mL to 0.78 mg/mL were prepared by a serial dilution of 1:2 resulting in final assay concentrations ranging from 1000.0 to 7.81 µg/mL. Cells were incubated with the test item for 24 h at 37°C. After exposure cells were stained with propidium iodide and cell viability was measured by FACS analysis.
The test item showed a strong shift of the fluorescence signal compared to the solvent control and thus the cytotoxic effect of the test item cannot be evaluated. It was assumed, that the test item is a strong fluorescent test chemical emitting at the same wavelength as FITC and interferes with the flow cytometric detection.
Therefore, the study was stopped after the first dose finding experiment. - Executive summary:
Starting from 100 mg/mL (in 0.9% NaCl) solutions of the test chemicals, eight stock solutions (eight concentrations) were prepared, by 2-fold serial dilutions using the corresponding solvent. These stock solutions were further diluted 250-fold into culture medium (working solutions). The working solutions were finally used for treatment by adding an equal volume of working solution to the volume of THP-1 cell suspension in a 96-well plate to achieve a further 2-fold dilution
For testing, THP-1 cells were pre-cultured for at least 48 h in culture flasks at a cell density of 0.1 – 0.2 x 106cells/mL. Prior to test item application, cells were harvested from the cell culture flask by centrifugation and were re-suspended in fresh culture medium at a density of 2 x 106 cells/mL. Then, 500 µL of the cell suspension were seeded into a 24 well flat-bottom plate (1 x 106cells/well).
The solvent controls and the test item working solutions were mixed 1:1 (v/v) with the cell suspensions prepared in the 24-well plate. Treated plates were incubated for 24 h±0.5 h at 37 °C±1 °C and 5% CO2.
After 24 h±0.5 h of exposure, cells were transferred into sample tubes and collected by centrifugation (approx. 250 x g). The supernatant was discarded and the remaining cells were washed twice with Dulbecco’s phosphate buffered saline (DPBS) containing 0.1% bovine serum albumin (BSA; i.e. FACS buffer). After washing, cells were re-suspended in 600 µL FACS buffer. 200 µL of the cell suspension were transferred into a FACS tube and stained by using propidium iodide (PI) solution at a final concentration of 0.625 µg/mL.
The PI uptake of the cells and therefore cytotoxicity was analysed immediately after the staining procedure by flow cytometry using an excitation wavelength of λ = 488 nm and an emission wavelength of λ > 650 nm. A total of 10,000 living (PI negative) cells were acquired.
The test item showed a strong shift of the fluorescence signal compared to the solvent control and thus the cytotoxic effect of the test item cannot be evaluated. It was assumed, that the test item is a strong fluorescent test chemical emitting at the same wavelength as FITC and interferes with the flow cytometric detection. Therefore, the study was stopped after the first dose finding experiment.
Referenceopen allclose all
All animals survived throughout the test period without showing any clinical signs.
All animals showed the expected weight development, which includes a weight loss of up to 2 g throughout the study.
Cysteine and Lysine Values of the Calibration Curve
Sample |
Cysteine Peptide |
Lysine Peptide |
||
Peak Area |
Peptide Concentration [mM] |
Peak Area |
Peptide Concentration [mM] |
|
STD1 |
4835.2368 |
0.5340 |
4453.7617 |
0.5340 |
STD2 |
2314.6648 |
0.2670 |
2214.0920 |
0.2670 |
STD3 |
782.4597 |
0.1335 |
1103.6776 |
0.1335 |
STD4 |
525.4504 |
0.0667 |
542.1525 |
0.0667 |
STD5 |
266.4071 |
0.0334 |
261.3623 |
0.0334 |
STD6 |
135.9798 |
0.0167 |
131.8409 |
0.0167 |
STD7 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
Depletion of the Cysteine Peptide
Cysteine Peptide |
||||||
Sample |
Peak Area |
Peptide Conc. [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
1381.2087 |
0.1629 |
71.03 |
71.19 |
0.17 |
0.24 |
1364.7275 |
0.1611 |
71.37 |
||||
1374.1948 |
0.1621 |
71.18 |
||||
Test Item |
0.0000 |
0.0109 |
100.00 |
100.00 |
0.00 |
0.00 |
0.0000 |
0.0109 |
100.00 |
||||
0.0000 |
0.0109 |
100.00 |
Depletion of the Lysine Peptide
Lysine Peptide |
||||||
Sample |
Peak Area |
Peptide Conc. [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
1562.8215 |
0.1884 |
62.85 |
62.34 |
0.45 |
0.72 |
1598.4821 |
0.1926 |
62.00 |
||||
1591.5383 |
0.1918 |
62.17 |
||||
Test Item |
3995.6775 |
0.4796 |
3.75 |
3.76 |
0.45 |
11.87 |
3976.6111 |
0.4773 |
4.21 |
||||
4013.6008 |
0.4818 |
3.31 |
Prediction Model 1
Cysteine 1:10/ Lysine 1:50 Prediction Model 1
Mean Cysteine andLysine PPD |
Reactivity Class |
DPRA Prediction² |
0.00% ≤ PPD ≤ 6.38% |
No or Minimal Reactivity |
Negative |
6.38% < PPD ≤ 22.62% |
Low Reactivity |
Positive |
22.62% < PPD ≤ 42.47% |
Moderate Reactivity |
|
42.47% < PPD ≤ 100% |
High Reactivity |
1 The numbers refer to statistically generated threshold values and are not related to the precision of the measurement.
2 DPRA predictions should be considered in the framework of an IATA.
Prediction Model 2
Cysteine 1:10 Prediction Model
Cysteine PPD |
ReactivityClass |
DPRA Prediction² |
0.00% ≤ PPD ≤ 13.89% |
No or Minimal Reactivity |
Negative |
13.89% < PPD ≤ 23.09% |
Low Reactivity |
Positive |
23.09% < PPD ≤ 98.24% |
Moderate Reactivity |
|
98.24% < PPD ≤ 100% |
High Reactivity |
Categorization of the Test Item
Predicition Model |
Prediction Model 1 |
Prediction Model 2 |
||||
Test Substance |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Test Item |
51.88 |
High Reactivity |
sensitizer |
100.00 |
High Reactivity |
sensitizer |
Positive Control |
66.77 |
High Reactivity |
sensitizer |
71.19 |
Moderate Reactivity |
sensitizer |
Results of the Cytotoxicity Measurement
Concentration [µM] |
Cell Viability [%] |
||||
Experiment 1 |
Experiment 2 |
Mean |
SD |
||
Solvent Control |
- |
100 |
100 |
100 |
0.0 |
Positive Control |
4.00 |
100.7 |
97.2 |
99.0 |
2.5 |
8.00 |
104.3 |
115.1 |
109.7 |
7.6 |
|
16.00 |
106.8 |
106.5 |
106.6 |
0.2 |
|
32.00 |
118.1 |
98.9 |
108.5 |
13.6 |
|
64.00 |
122.0 |
99.4 |
110.7 |
16.0 |
|
Test Item |
0.98 |
128.3 |
108.3 |
118.3 |
14.1 |
1.95 |
134.1 |
108.1 |
121.1 |
18.3 |
|
3.91 |
139.9 |
123.2 |
131.5 |
11.8 |
|
7.81 |
159.4 |
141.3 |
150.3 |
12.8 |
|
15.63 |
189.8 |
167.6 |
178.7 |
15.7 |
|
31.25 |
216.6 |
188.2 |
202.4 |
20.0 |
|
62.50 |
214.6 |
179.1 |
196.9 |
25.2 |
|
125.00 |
185.5 |
131.3 |
158.4 |
38.3 |
|
250.00 |
115.5 |
78.4 |
97.0 |
26.3 |
|
500.00 |
31.2 |
33.4 |
32.3 |
1.5 |
|
1000.00 |
7.2 |
9.3 |
8.3 |
1.5 |
|
2000.00 |
0.1 |
0.2 |
0.2 |
0.1 |
Induction of Luciferase Activity Experiment 1
Experiment 1 |
Concentration [µM] |
Fold Induction |
Significance |
||||
Rep. 1 |
Rep. 2 |
Rep. 3 |
Mean |
SD |
|||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.08 |
1.13 |
1.21 |
1.14 |
0.07 |
|
8.00 |
1.18 |
1.14 |
1.25 |
1.19 |
0.06 |
|
|
16.00 |
1.34 |
1.30 |
1.40 |
1.35 |
0.05 |
|
|
32.00 |
1.58 |
1.61 |
1.73 |
1.64 |
0.08 |
* |
|
64.00 |
2.39 |
2.60 |
2.66 |
2.55 |
0.14 |
* |
|
Test Item |
0.98 |
1.72 |
1.77 |
1.73 |
1.74 |
0.02 |
* |
1.95 |
1.47 |
1.94 |
1.81 |
1.74 |
0.24 |
* |
|
3.91 |
1.27 |
1.95 |
2.05 |
1.76 |
0.42 |
* |
|
7.81 |
2.11 |
2.72 |
2.22 |
2.35 |
0.33 |
* |
|
15.63 |
1.69 |
2.78 |
2.97 |
2.48 |
0.69 |
* |
|
31.25 |
3.35 |
4.10 |
4.17 |
3.87 |
0.46 |
* |
|
62.50 |
4.94 |
6.67 |
6.03 |
5.88 |
0.88 |
* |
|
125.00 |
15.15 |
21.96 |
20.25 |
19.12 |
3.54 |
* |
|
250.00 |
33.38 |
54.98 |
44.02 |
44.12 |
10.80 |
* |
|
500.00 |
13.96 |
23.03 |
16.66 |
17.88 |
4.66 |
* |
|
1000.00 |
7.60 |
9.19 |
8.41 |
8.40 |
0.80 |
* |
|
2000.00 |
1.52 |
1.11 |
0.70 |
1.11 |
0.41 |
|
* = significant induction according to Student’s t-test, p<0.05
Induction of Luciferase Activity Experiment 2
Experiment 2 |
Concentration [µM] |
Fold Induction |
Significance |
||||
Rep. 1 |
Rep. 2 |
Rep. 3 |
Mean |
SD |
|||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.25 |
1.21 |
1.11 |
1.19 |
0.07 |
|
8.00 |
1.51 |
1.41 |
1.19 |
1.37 |
0.16 |
|
|
16.00 |
1.51 |
1.71 |
1.29 |
1.50 |
0.21 |
* |
|
32.00 |
2.22 |
2.24 |
1.86 |
2.11 |
0.21 |
* |
|
64.00 |
3.60 |
3.90 |
3.36 |
3.62 |
0.27 |
* |
|
Test Item |
0.98 |
1.33 |
1.19 |
1.42 |
1.31 |
0.11 |
|
1.95 |
1.31 |
1.30 |
2.01 |
1.54 |
0.41 |
|
|
3.91 |
1.56 |
1.43 |
1.97 |
1.65 |
0.28 |
* |
|
7.81 |
2.10 |
1.93 |
2.29 |
2.10 |
0.18 |
* |
|
15.63 |
2.52 |
3.07 |
3.42 |
3.01 |
0.45 |
* |
|
31.25 |
4.31 |
4.72 |
3.72 |
4.25 |
0.50 |
* |
|
62.50 |
4.98 |
5.39 |
7.88 |
6.08 |
1.57 |
* |
|
125.00 |
21.91 |
28.08 |
21.96 |
23.98 |
3.55 |
* |
|
250.00 |
34.39 |
39.32 |
39.63 |
37.78 |
2.94 |
* |
|
500.00 |
16.50 |
14.42 |
16.15 |
15.69 |
1.11 |
* |
|
1000.00 |
8.86 |
6.65 |
6.56 |
7.36 |
1.30 |
* |
|
2000.00 |
0.83 |
0.18 |
0.30 |
0.44 |
0.34 |
|
* = significant induction according to Student’s t-test, p<0.05
Induction of Luciferase Activity – Overall Induction
Overall Induction |
Concentration [µM] |
Fold Induction |
Significance |
|||
Experiment 1 |
Experiment 2 |
Mean |
SD |
|||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.14 |
1.19 |
1.17 |
0.04 |
|
8.00 |
1.19 |
1.37 |
1.28 |
0.13 |
|
|
16.00 |
1.35 |
1.50 |
1.43 |
0.11 |
|
|
32.00 |
1.64 |
2.11 |
1.87 |
0.33 |
|
|
64.00 |
2.55 |
3.62 |
3.08 |
0.76 |
|
|
Test Item |
0.98 |
1.74 |
1.31 |
1.53 |
0.30 |
|
1.95 |
1.74 |
1.54 |
1.64 |
0.14 |
* |
|
3.91 |
1.76 |
1.65 |
1.70 |
0.07 |
* |
|
7.81 |
2.35 |
2.10 |
2.23 |
0.17 |
* |
|
15.63 |
2.48 |
3.01 |
2.74 |
0.37 |
* |
|
31.25 |
3.87 |
4.25 |
4.06 |
0.27 |
* |
|
62.50 |
5.88 |
6.08 |
5.98 |
0.14 |
* |
|
125.00 |
19.12 |
23.98 |
21.55 |
3.44 |
* |
|
250.00 |
44.12 |
37.78 |
40.95 |
4.49 |
* |
|
500.00 |
17.88 |
15.69 |
16.78 |
1.55 |
* |
|
1000.00 |
8.40 |
7.36 |
7.88 |
0.74 |
* |
|
2000.00 |
1.11 |
0.44 |
0.77 |
0.48 |
|
* = significant induction according to Student’s t-test, p<0.05
Additional Parameters
Parameter |
Experiment 1 |
Experiment 2 |
Mean |
SD |
EC1.5[µM] |
n/a |
1.78 |
n/a |
n/a |
Imax |
44.12 |
37.78 |
40.95 |
4.49 |
IC30[µM] |
385.00 |
296.50 |
340.75 |
62.58 |
IC50[µM] |
444.29 |
407.59 |
425.94 |
25.95 |
n/a – not applicable
Acceptance Criteria
Criterion |
Range |
Experiment 1 |
pass/fail |
Experiment 2 |
pass/fail |
CV Solvent Control |
< 20% |
9.6 |
pass |
6.4 |
pass |
No. of positive control concentration steps with significant luciferase activity induction >1.5 |
≥ 1 |
2.0 |
pass |
3.0 |
pass |
EC1.5 PC |
7 < x < 34 µM |
24.29 |
pass |
15.89 |
pass |
Induction PC at 64 µM |
2.00 < x < 8.00 |
2.55 |
pass |
3.62 |
pass |
Historical Data
Acceptance Criterion |
Range |
Mean |
SD |
N |
CV Solvent Control |
< 20% |
11.3 |
3.3 |
41 |
No. of positive control concentration steps with significant luciferase activity induction >1.5 |
≥ 1 |
2.3 |
0.6 |
41 |
EC1.5 PC |
7 < x < 34 µM |
20.4 |
6.7 |
41 |
Induction PC at 64 µM |
2.00 < x < 8.00 |
3.3 |
1.1 |
41 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available (further information necessary)
Justification for classification or non-classification
Due to the equivocal results of non-animal approches and the limited applicability of these test systems the LLNA was performed to adress skin sensitisation potential of the test item. Based on the results of LLNA and according to Commission Regulation (EU) No 286/2011 (CLP) as well as GHS (Globally Harmonized Classification System) the test item has obligatory labelling requirement for skin sensitisation and is classified into Category 1B.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.